Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

A study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day ...

The FDA recently announced a voluntary recall of a popular Sinu Cleanse nasal spray sold at retailers like H-E-B, Walgreens, ...

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).

Nasal decongestants, often used during cold and allergy seasons, can negatively impact brain health when used long-term or in ...

Discover how timolol eye drops, typically used for glaucoma, show promise in acute migraine relief. Learn about the research, ...

Childhood psychiatrists insist the drugs, for attention-deficit/hyperactivity disorder (ADHD) and depression, are nonaddictive and proven safe and say they are more concerned about young Americans ...

Investing during a period of economic depression or recession can be daunting. However, choosing the right depression stocks can help you weather a period of uncertainty and protect your financial ...

Feb. 19, 2025 — A new study of more than 1400 adults who gamble and play online video games has found loot box buying is associated with real-world gambling, video gaming addiction, and other ...